COMPARATIVE ANALYSIS OF THE EFFECTIVENESS OF MONO- AND COMBINATION THERAPY WITH PROSTAGLANDIN E1 DRUGS IN THE TREATMENT OF PATIENTS WITH ERECTILE DYSFUNCTION AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY

Background. Erectile dysfunction (ED) is one of the most frequent complications after robot-assisted radical prostatectomy (RARP). The probability of ED development is strongly increased in the presence of concomitant pathologies, such as diabetes mellitus and hypertension, as well as in the presence of marked weakness of pelvic floor muscles. The immediate cause of ED after RARP is intraoperative trauma to the neurovascular bundles (NVB) of the prostate gland. Purpose. To perform a comparative analysis of the efficacy of monotherapy with FDE-5 inhibitors versus combined therapy with prostaglandin E1 drugs after robot-assisted radical prostatectomy. Conclusion. In the treatment of erectile dysfunction in patients after nerve-sparing RARP, combined administration of phosphodiesterase type 5 inhibitors (PDE-5) and alprostadil is more effective than monotherapy with PDE-5 inhibitors.